Amgen Inc. said Thursday that it was shelving plans for its big but postponed Irish plant. It also announced it will partner with Italian firm to market Amgen’s products in Italy.

Amgen said its decision to postpone indefinitely building its $1.1 billion production plant in southern Ireland was “based purely on developments relating to Amgen’s global business” and had nothing to do with relations with the country or the town. Amgen said in April that it was postponing construction of the plant. The plant would have created about 1,100 jobs.

The Thousand Oaks biotech giant also said it was partnering with Dompe Biotec SpA in a joint venture that will be called Amgen Dompe SpA. It will serve as an Amgen affiliate, employing current Amgen and Dompe staff as well as Amgen research and development staff in Italy. Dompe is based in Milan.